Lau Gloria H W, Auyeung Tung Wai, Joyce Emer, McDonagh Julee, Yu Ka Man, Woo Jean, Lee Jenny S W, Jha Sunita, Macdonald Peter S, Fung Erik
Gerald Choa Cardiac Research Centre and Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Centre for Cardiovascular Genomics & Medicine and HK HOPE, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
CUHK Jockey Club Institute of Ageing, The Chinese University of Hong Kong, Hong Kong, China.
J Card Fail. 2025 Jun 16. doi: 10.1016/j.cardfail.2025.03.021.
Heart failure (HF) is a clinical syndrome associated with a range of pathophysiological disorders, including secondary sarcopenia that reduces patients' quality of life, mobility, physical fitness, and capacity to undergo rehabilitation and recovery from acute decompensation. Although international expert writing groups have convened and developed consensus documents for sarcopenia, the vast majority of the content has focused on the disorder from the aging perspective. HF is rarely or never considered in the available consensus statements and recommendations. Moreover, there are differences in the sarcopenia diagnostic criteria pertaining to race/ethnicity (translating into differences in body composition and anthropometry), investigative methodologies, practice patterns, and variations in access to health care resources across nations that are not discussed in the current HF-management guidelines. Here, we review the key contents of the recent major international consensus documents concerning sarcopenia that were published between 2019 and 2024. We highlight the gaps in knowledge (eg, sarcopenic obesity, cardiac atrophy/wasting) and recent developments in HF treatment (eg sodium glucose co-transporter 2 inhibitors) and interventions (eg, rehabilitation, inspiratory muscle training) that may benefit sarcopenia; and we reformulate the 4-step pathway of early screening, investigation, diagnosis and severity determination (Find-Assess-Confirm-Severity) for sarcopenia as a vital part of HF management under a multidisciplinary care team.
心力衰竭(HF)是一种与一系列病理生理紊乱相关的临床综合征,包括继发性肌肉减少症,后者会降低患者的生活质量、活动能力、身体素质以及从急性失代偿中康复和恢复的能力。尽管国际专家写作小组已经召开会议并制定了关于肌肉减少症的共识文件,但绝大多数内容都是从衰老的角度关注这种疾病。现有的共识声明和建议很少或从未考虑过HF。此外,在肌肉减少症的诊断标准方面,存在种族/民族差异(转化为身体成分和人体测量学的差异)、调查方法、实践模式以及各国在获得医疗保健资源方面的差异,而当前的HF管理指南中并未讨论这些内容。在此,我们回顾了2019年至2024年间发表的有关肌肉减少症的近期主要国际共识文件的关键内容。我们强调了知识空白(如肌肉减少性肥胖、心脏萎缩/消瘦)以及HF治疗(如钠葡萄糖协同转运蛋白2抑制剂)和干预措施(如康复、吸气肌训练)方面的最新进展,这些可能对肌肉减少症有益;并且我们重新制定了肌肉减少症早期筛查、调查、诊断和严重程度判定的四步路径(查找-评估-确认-严重程度),将其作为多学科护理团队下HF管理的重要组成部分。